CANNASSURE THERAPEUTICS LTD

Ajouter à une liste

Instrument Inactif

Autres langues Cannassure Therapeutics Ltd TEL AVIV STOCK EXCHANGE

Actions

CSURE

IL0001110134

Développement et opérations immobilières

Autres langues

03/05	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2025
03/05	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt
13/11	Y.B Urban Renewal - Residential Development Ltd announced that it expects to receive ILS 0.53001 million in funding
10/09/25	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2025
01/09/24	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2024
11/07/24	Cannassure Therapeutics Ltd will Change its Name to Y.B URBAN RENEWAL - RESIDENTIAL DEVELOPMENT LTD
27/03/24	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
27/03/24	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt
31/08/23	Cannassure Therapeutics Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
26/03/23	Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
09/08/21	Cannassure Was Granted A Patent for an Oral Delivery Method of Cannabis and Cannabinoids Compositions by the Israel Patents Authority
26/02/21	DanCann Pharma A/S : publishes Year-end report for 2020
18/01/21	Cannassure Therapeutics : DanCann Pharma's strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology
18/01/21	Lipidor : and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO technology
15/12/20	DanCann Pharma A/S : enter exclusive agreement with Cannassure Therapeutics to be multinational distributor for Scandinavia (Denmark, Norway, Sweden, and Finland)
19/11/20	Lipidor : publishes interim report for Q3 2020
30/09/20	Lipidor : announces positive outcome of feasibility study for development of topical medical cannabis products based on the company's AKVANO® technology
11/12/19	Cannassure Therapeutics : Ltd and Lipidor AB Enter a Feasibility Study and Licence Option Agreement for Development and Sales of Topical Medical Cannabis Products Based on AKVANO Technology
10/12/19	Lipidor (Nasdaq First North: LIPI) and Cannassure (TASE:CSURE) enter a feasibility study and licence option agreement for development and sales of topical medical cannabis products

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Les meilleurs outils réservés aux abonnés pour augmenter la performance de vos investissements !